Bausch Health Companies Inc. · TSX:BHC
Bausch Health Companies — Valeant Pharmaceuticals International — Debt Investor Presentation (September 2013)
23 slides from Bausch Health Companies's debt investor presentation, Sep 9, 2013
Slide 1: Valeant Pharmaceuticals Lenders' Presentation September 9, 2013
Valeant Pharmaceuticals International, Inc. Lenders’ Presentation September 9 , 2013
Slide 2: Forward-looking Statements
Forward - looking Statements Forward - looking Statements Certain statements made in this presentation may constitute forward - looking statements, including, but not limited to, statements regarding the performance of the business, synergies, pipeline approvals, patent risk and product exclusivity,
Slide 3: Agenda
Agenda Executive Summary & Transaction Overview Amendment Overview & Timeline Business Update Q2 2013 Results Bausch + Lomb Update Questions and Answers 3
Slide 4: Transaction Overview
Transaction Overview Way VALEANT
Slide 5: Executive Summary
5 Executive Summary Valeant Pharmaceuticals International, Inc . (“Valeant” or the “Company”) is a multinational specialty pharmaceutical company with a diverse global product portfolio Q 2 2013 Highlights Total Revenue for the quarter, at $ 1 , 096 million ; an increase of 41 % over the prior
Slide 6: Capitalization Pro forma for Bausch + Lomb Acquisition
6 Capitalization Pro forma for Bausch + Lomb Acquisition ($ in millions) Note: Debt amounts are face value s . 1 Does not include local working capital lines with outstanding balances of approx imately $54 million as of June 30, 2013. 2 Leverage multiples calculated net of $350 million cash as permi
Slide 7: Summary Terms - Term Loan B - Series C & D
Summary Terms - Term Loan B - Series C & D Terms Term Loan B – Series C & D Borrower Valeant Pharmaceuticals International, Inc (the “Borrower”) Guarantors Material direct and indirect wholly - owned subsidiaries of the Borrower subject to customary exclusions (consistent with existing Senior Se
Slide 8: Transaction Timetable
8 Transaction Timetable Dates Event September 9 th Lenders’ Call September 12 th Commitments Due September 13 th Allocate September 17 th Close and fund 8 September 2013 S M T W T F S 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 Holiday Key Date
Slide 9: Business Update
Business Update Way VALEANT
Slide 10: Strong Q2 2013 Earnings and Cash Generation Performance
Strong Q2 2013 Earnings and Cash Generation Performance Q2 2013 Q2 2012 2013 vs 2012 Total Revenue $1.096 B $775M 1 41% Product Sales $1.064 B $743M 43% Cash EPS $1.34 $0.87 1 54% Adjusted Cash Flow $423 M $262 M 1 61% 1 Excludes milestone of $45M related to the U.S. launch of Potiga ® 10
Slide 11: Q2 2013 Organic Growth Same Store Sales
Q2 2013 Organic Growth Same Store Sales As Reported Excluding Zovirax ® Ointment Excluding Zovirax ® Franchise U.S. Promoted - 5% 4% 7% U.S. Neuro 2% 2% 2% Canada / Australia 4% 4% 4% Central/Eastern Europe 13% 13% 13% Latin America 17% 17% 17% South East Asia/South Africa 11% 11% 11% Pro Forma U.S.
Slide 12: Key Highlights of Q2 2013
Key Highlights of Q2 2013 OraPharma Double digit growth every quarter since acquisition CeraVe ® 50%+ growth year over year Aesthetics Best quarter since Medicis first launched Poland YTD 1 growth rate (11%); significantly higher than the market rate (6%) Russia YTD 1 growth rate
Slide 13: Revenue Performance of Past Acquisitions
Revenue Performance of Past Acquisitions LTM prior to close as been adjusted to reflect 2013 foreign exchange rates Note: Excludes deals under $75 million purchase price and transactions completed in 2013 1 Standalone Biovail, prior to its merger with Legacy Valeant 13 Acquisition Date LTM prior to
Slide 14: Performance of Past Acquisitions Cumulative Cash Flow vs. Deal Model
Performance of Past Acquisitions Cumulative Cash Flow 1 vs. Deal Model Note: Excludes deals under $75 million purchase price and transactions completed in 2013 Acquisition Behind by More Than 10% On Track Ahead by More Than 10% Coria P Aton P Biovail ( excl Zovirax ® ) P PharmaSwiss P Zovirax ® (US
Slide 15: Valeant Pipeline Update
Valeant Pipeline Update Efinaconazole Provisionally accepted brand name: Jublia ® Met with FDA in July 2013 to discuss container closure apparatus Agreed upon plan with FDA to address concerns Expect to launch in Q2 / Q3 2014 Acanya ® Acanya 2015 patent extended to 2029 Acanya LCM pr
Slide 16: Bausch + Lomb Update
Bausch + Lomb Update Way VALEANT
Slide 17: What We Have Learned Since Announcement
What We Have Learned Since Announcement VRX and B+L Have Similar Cultures Performance based Teamwork oriented, willingness to wear multiple hats and accept change Excited that so many of the key B+L leaders have joined Valeant Strategic Rationale Has Been Reinforced Eye Health is an attr
Slide 18: Synergy Update
Synergy Update >$800 million in synergies already identified Expect 10 - 15% combined company headcount reduction No impact to North American field force and minimal impact to ROW field forces Less than 5% of total synergies will come from reductions in global field forces We would expect
Slide 19: Limited Patent Risk for Combined Company
Limited Patent Risk for Combined Company 2013 2014 2015 2016 2017 Products 1) Bromday ® 2) Retin - A Micro ® 3) Wellbutrin ® XL (CAD) 4) Vanos ® 1) Atralin ® 2) Tiazac ® (CAD) 3) Lotemax ® Suspension 4) Alrex ® 1) Xenazine ® 1) Ziana ® 2) Zirgan ® 3) Targretin ® 1) Lotemax ® Gel 2) Macugen ® Total 2
Slide 20: Questions and Answers
Questions and Answers Way VALEANT
Slide 21: Appendix
Appendix Way VALEANT
Slide 22: Valeant Adjusted EBITDA Reconciliation
Valeant Adjusted EBITDA Reconciliation ($ in millions) 22 LTM Consolidated Adjusted EBITDA (As of June 30, 2013) (a) Consolidated Net Income reflects the adjustment to ( i ) exclude gains and losses on asset sales and (ii) net income or loss derived from joint v entures. (b) Restructuring Costs as d
Slide 23: Bausch & Lomb Adjusted EBITDA Reconciliation
Bausch & Lomb Adjusted EBITDA Reconciliation ($ in millions) 23 LTM Consolidated Adjusted EBITDA (As of June 30, 2013) (a) Reflects write - down of investments in equity securities using the cost method of accounting. (b) Reflects costs associated with the acquisition and integration of Waicon , IST
Valeant Pharmaceuticals International — Debt Investor Presentation (September 2013) on 6ix